Amino acid amine-borane compound as well as preparation method and application thereof
By developing amino acid amine-borane compounds, the problems of difficulty in synthesis, poor water solubility and insufficient tumor targeting are solved, efficient boron atom uptake and good water solubility are achieved, and the treatment effect is significantly improved.
Patent Information
- Application Number
- CN202411177093.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The existing boron neutron capture therapy (BNCT) drugs have difficulty synthesis, poor water solubility and insufficient tumor targeting, resulting in poor treatment results.
Develop amino acid amine-borane compounds and their preparation methods, and form good water-soluble and high tumor targeting by dissolving amino acids with N,O-bis(trimethylsilyl)acetamide and reacting with borane complexes. amino acid amine-borane compounds.
It improves the uptake capacity of tumor cells to boron atoms, has water solubleness of more than 35 times that of commercially available drugs, and is non-toxic, and has potential for new boron delivery agents.
Smart Images

Figure CN119039333A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of tumor therapeutic drugs, and in particular relates to an amino acid amine-borane compound and a preparation method and application thereof. Background Art
[0002] Malignant tumor is one of the major diseases that seriously endangers human life and health. There is a high practical demand for the development of efficient diagnosis and treatment technology for cancer, and great progress has been made in the treatment of malignant tumors, including surgery, drug therapy, radiotherapy and immunotherapy. Among them, about 70% of cancer patients choose radiotherapy every year. With the development of modern medical technology, radiotherapy technology is updated with each passing day, and has developed from non-selective radiotherapy technology to proton and heavy ion radiotherapy with certain longitudinal energy selection. Despite this, malignant tumors such as high-grade gliomas are still extremely resistant to almost all current treatment methods. As a cell-level precise binary targeted tumor treatment technology, boron neutron capture therapy (BNCT) combines biological targeting with heavy ion effects to selectively kill cancer cells at the cellular scale. It can be completed with only 1-2 irradiations. It has outstanding advantages for mid- and late-stage malignant tumors that are difficult to operate on and cannot be treated with traditional radiotherapy and chemotherapy. BNCT will carry 10 B's targeted drug is injected into the patient's body. 10 B will specifically gather in the tumor tissue, and irradiate the affected area with epithermal neutrons. 10 B occurs 10 B(n,α) 7 Li nuclear reactions to form its isotopes 11 B. Then, 11 B splits to produce high energy 7 The range of Li ions and α particles is only about one cell diameter. Cancer cells are precisely killed because their DNA is irreversibly broken under the action of heavy ions, while normal cells are basically undamaged.
[0003] At present, BNCT has experienced a spurt of development, with the neutron source shifting from reactors to more economical, safe and reliable accelerator neutron sources, achieving a key technological breakthrough in neutron beam acquisition. However, the development of BNCT-targeted boron-containing drugs still faces difficulties. Currently, only 4-dihydroxyboryl-L-phenylalanine (BPA) and sodium 11-hydrothiodiboride (BSH) are used in clinical practice, and BPA is the only clinical therapeutic drug on the market worldwide. However, BPA has insufficient tumor specificity, short blood half-life and retention time, and extremely poor solubility, resulting in low boron atom enrichment in tumor tissue. Clinically, BPA must be treated with fructose as an excipient to improve its water solubility and injected intravenously in large quantities, which has significant toxic side effects on the kidneys and seriously affects the efficacy of BNCT. Therefore, it is crucial to develop a class of small molecule organic boron compounds with economical and efficient synthesis process, easy-to-obtain raw materials, good water solubility, and potential broad tumor targeting as candidate drug molecules to improve the clinical treatment effect of BNCT. Summary of the invention
[0004] In order to overcome the shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide an amino acid amine-borane compound and a preparation method and application thereof, so as to solve the technical problems of the existing BNCT drug synthesis difficulty, poor water solubility and insufficient tumor targeting.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] The first aspect of the present invention discloses an amino acid amine-borane compound having a compound of formula (I) or a pharmaceutically acceptable salt thereof, and stereoisomers, isotopic products and derivatives of the compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0007]
[0008] Wherein, R is a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, an alkyl group containing a substituent, an aryl group containing a substituent or a heteroaryl group containing a substituent; R' is a hydrogen atom, an alkyl group or an alkyl group containing a substituent.
[0009] The second aspect of the present invention discloses a method for preparing the above-mentioned amino acid amine-borane compound, comprising the following steps:
[0010] 1) dissolving an amino acid and N,O-bis(trimethylsilyl)acetamide in an organic solvent to react to obtain a silicon-protected amino acid;
[0011] 2) adding a borane complex to the reaction mixture of step 1 to obtain an amino acid amine-borane compound.
[0012] The third aspect of the present invention discloses the use of the above amino acid amine-borane compound in the preparation of a pharmaceutical preparation for BNCT.
[0013] Preferably, the BNCT pharmaceutical preparation is a drug or preparation for treating tumors, or a drug or preparation for inhibiting the progression of tumors.
[0014] More preferably, the drug or preparation for inhibiting the progression of tumor development is a drug for inhibiting the progression of malignant tumors or metastatic tumors.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] The amino acid amine-borane compound provided by the present invention has a structure as shown in formula (I). In the structure, the amino group of the amino acid has a pair of lone pairs of electrons, the boron atom on the borane has an empty orbital, and the lone pairs of electrons on the amino group are very easy to coordinate with the boron atom to form an amine-borane product. By protecting the carboxyl functional group in the amino acid, a silicon-based protected intermediate is obtained to reduce the polarity of the amino acid molecule. After that, the amine-borane derivative is obtained by coordinating the amino group with the borane, and then the amino acid amine-borane product is successfully obtained by deprotection. Since the structure is similar to that of amino acids, it can be transported to tumor cells through amino acid transporters on the surface of the cell membrane. The preparation method of the entire compound is simple and low-cost, and is suitable for the synthesis of various amino acids and amino acid structural analogs. Cell experiment results show that the uptake capacity of tumor cells for such compounds is much higher than that of BPA, a clinical treatment drug for boron neutron capture, and there is no sign of any toxicity, indicating that it has important potential as a new boron delivery agent for boron neutron capture therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Phenylalanine amine-borane of Example 1 1 H NMR spectrum;
[0018] Figure 2 Phenylalanine amine-borane of Example 1 13 C NMR spectrum;
[0019] Figure 3 Phenylalanine amine-borane of Example 1 11 B NMR spectrum;
[0020] Figure 4 is the tryptophan amine-borane of Example 2 1 H NMR spectrum;
[0021] Figure 5 is the tryptophan amine-borane of Example 2 13 C NMR spectrum;
[0022] Figure 6 is the tryptophan amine-borane of Example 2 11 B NMR spectrum.
[0023] Figure 7 is the methionine amine-borane of Example 3 1 H NMR spectrum;
[0024] Figure 8 is the methionine amine-borane of Example 3 13 C NMR spectrum;
[0025] Fig. 9 is the methionine amine-borane of Example 3 11 B NMR spectrum;
[0026] Fig.10 is the threonine amine-borane of Example 4 1 H NMR spectrum;
[0027] Fig.11 is the threonine amine-borane of Example 4 13 C NMR spectrum;
[0028] Fig.12 is the threonine amine-borane of Example 4 11 B NMR spectrum;
[0029] Fig.13 Isoleucine amine-borane of Example 5 1 H NMR spectrum;
[0030] Fig.14 Isoleucine amine-borane of Example 5 13 C NMR spectrum;
[0031] Fig.15 Isoleucine amine-borane of Example 5 11 B NMR spectrum;
[0032] Fig.16 This is a diagram showing the cytotoxicity test results of compound 1 of the present invention;
[0033] Fig.17 This is a diagram showing the cytotoxicity test results of compound 2 of the present invention;
[0034] Fig.18 This is a diagram showing the cytotoxicity test results of compound 3 of the present invention;
[0035] Fig.19 This is a diagram showing the cytotoxicity test results of compound 4 of the present invention;
[0036] Fig. 20 This is a diagram showing the cytotoxicity test results of compound 5 of the present invention;
[0037] Fig.21This is a diagram showing the cytotoxicity test results of compound 6 of the present invention;
[0038] Fig. 22 This is a diagram showing the cytotoxicity test results of compound 7 of the present invention;
[0039] Fig.23 This is a diagram showing the cytotoxicity test results of compound 8 of the present invention;
[0040] Fig.24 This is a graph showing the experimental results of boron atom uptake by compounds 1 to 7 of the present invention in 4T1 cells. DETAILED DESCRIPTION
[0041] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.
[0042] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.
[0043] As used herein, the term "boron neutron capture therapy" (BNCT) refers to a method of treating tumors, comprising the steps of administering a boron-containing compound to a subject in need of treatment and irradiating the subject with thermal neutrons. The term "tumor" refers to the growth of a tissue in which cell proliferation is uncontrolled and progressive. Uncontrolled proliferation is a state that is different from normal cell proliferation, such as a state in which the cell proliferation rate is significantly increased. The term "progressive" refers to a strong progression or increase. The term "tumor cell" refers to a cell in histology. The term "tumor treatment" refers to the treatment of diseases caused by or related to tumors. Unless otherwise specified, "→" in formula (I) represents a coordination bond.
[0044] The first aspect of the present invention provides an amino acid amine-borane compound, the structure of which is shown in formula (I):
[0045]
[0046] Wherein, R is a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, an alkyl group containing a substituent, an aryl group containing a substituent or a heteroaryl group containing a substituent; R′ is a hydrogen atom, an alkyl group or an alkyl group containing a substituent; the alkyl group or the alkyl group containing a substituent includes but is not limited to Aryl or aryl containing substituents include but are not limited to Heteroaryl or heteroaryl containing substituents includes but is not limited to
[0049] Preferably, the pharmaceutically acceptable salt of the amino acid amine-borane compound is an ammonium salt, a lithium salt, a sodium salt, a potassium salt, a rubidium salt, a cesium salt, a magnesium salt or a calcium salt thereof.
[0050] Preferably, all enantiomers of the amino acid amine-borane compound or a pharmaceutically acceptable salt thereof, and mixtures of enantiomers in any ratio.
[0051] Preferably, the enantiomeric isotopic product of the amino acid amine-borane compound or a pharmaceutically acceptable salt thereof contains 10 B. 11 B. 12 C. 13 C. 18 O or 2 H atom.
[0052] The second aspect of the present invention provides a method for preparing the above-mentioned amino acid amine-borane compound, comprising the following steps:
[0053]
[0054] (1) dissolving a natural or non-natural amino acid or N-substituted amino acid (1.0 equivalent) and N,O-bis(trimethylsilyl)acetamide (BSA; 1.0 to 5.0 equivalents) in an organic solvent, and reacting to obtain a silicon-protected amino acid derivative;
[0055] Among them, N,O-bis(trimethylsilyl)acetamide is used as a protecting agent for the carboxyl group.
[0056]
[0057] (2) Adding a borane complex (1.0 to 5.0 equivalents) to a solution of a silicon-protected amino acid derivative, and removing the silicon-protecting group after the reaction is completed to obtain an amino acid amine-borane compound.
[0058] The third aspect of the present invention provides the use of the above-mentioned amino acid amine-borane compound in the preparation of a pharmaceutical preparation for BNCT. BNCT can be used to treat various types of tumors or inhibit the progression of tumor development.
[0059] Among them, the boron neutron capture therapy drug is a drug for treating tumors or a drug for inhibiting the development of tumors; the tumor includes but is not limited to malignant tumors; the malignant tumors include but are not limited to glioblastoma multiforme, malignant meningioma, intramedullary spinal glioma, advanced or recurrent head and neck cancer, thyroid cancer, malignant melanoma, recurrent breast cancer, metastatic liver cancer, malignant brain tumors, osteosarcoma, lung cancer, cutaneous squamous cell carcinoma or nasopharyngeal carcinoma.
[0060] The amino acid amine-borane compound can be directly dissolved in physiological saline, phosphate buffer solution, sterile water or glucose solution to prepare a boron medicine preparation for infusion.
[0061] The amino acid amine-borane compound does not need to add any auxiliary materials, its water solubility can reach more than 35 times that of the commercially available BPA boron drug, and the boron atom uptake of tumor cells can reach 5 to 26 times that of the commercially available BPA boron drug.
[0062] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0063] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples, unless otherwise specified, are conventional commercial products, and their specifications are conventional specifications in the art.
[0064] 1. Preparation of amino acid amine-borane compounds
[0065] Example 1: Preparation of phenylalanine amine-borane
[0066]
[0067] Phenylalanine (165.2 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (306.6 mg, 1.5 mmol) were dissolved in 1,4-dioxane (2 mL) and stirred at 10 °C for 24 hours. Borane dimethyl sulfide complex (1 M, 1 mL, 1.0 mmol) was added to the reaction mixture and stirred for 24 hours. After the reaction was completed, 2 mL of water was added to quench the reaction and phenylalanine amine-borane (compound 1) was isolated. The nuclear magnetic resonance spectrum is shown in FIG. Figures 1 to 3 shown.
[0068] 1H NMR (400MHz, D2O) δ7.42–7.23(m,5H),3.38(t,J=6.5Hz,1H),3.05–2.99(m,2H),1.43(s,3H). 13 C NMR (101MHz, D2O) δ177.9,139.0,133.3,133.1,131.6,69.0,40.3. 11 BNMR (128MHz, D2O) δ-21.3.
[0069] Example 2: Preparation of tryptophan amine-borane
[0070]
[0071] Tryptophan (204.2 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (613.2 mg, 3.0 mmol) were dissolved in chloroform (3 mL) and stirred at 20 °C for 36 hours. Borane tetrahydrofuran complex (1 M, 2 mL, 2.0 mmol) was added to the reaction mixture and stirred for 24 hours. After the reaction was completed, 2 mL of methanol was added to quench the reaction and tryptophan amine-borane (compound 2) was isolated. The NMR spectrum is shown in the figure below. Figures 4 to 6 shown.
[0072] 1 H NMR(400MHz,D2O)δ7.71(d,J=8.0Hz,1H),7.49(d,J=8.2Hz,1H),7.31–7.20(m,2H),7.16(q,J=7 .5Hz,1H),3.46(t,J=6.2Hz,1H),3.36–3.28(m,1H),3.17(dd,J=14.9,7.0Hz,1H),1.26(s,3H). 13 C NMR (101MHz, D2O) δ178.5,140.3,130.6,129.0,126.1,123.4,122.4,115.9,111.55,59.0,30.35. 11 B NMR (128 MHz, D2O) δ -22.2.
[0073] Example 3: Preparation of methionine amine-borane
[0074]
[0075] Methionine (149.2 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (306.6 mg, 1.5 mmol) were dissolved in tetrahydrofuran (3 mL) and stirred at 50 °C for 36 hours. Borane dimethyl sulfide complex (1 M, 1 mL, 1.5 mmol) was added to the reaction mixture and stirred for 24 hours. After the reaction was completed, 2 mL of methanol was added to quench the reaction and methionine amine-borane (compound 3) was isolated. The NMR spectrum is shown in the figure below. Figures 7 to 9 shown.
[0076] 1 H NMR (400MHz, D2O) δ3.15 (t, J = 6.2 Hz, 1H), 2.44 (td, J = 7.5, 4.1 Hz, 2H), 1.99–1.83 (m, 5H), 1.60–0.73 (m, 3H). 13 C NMR (101MHz, D2O) δ177.4, 61.7, 30.6, 28.9, 14.0. 11 BNMR (128MHz, D2O) δ-21.3.
[0077] Example 4: Preparation of threonine amine-borane
[0078]
[0079] Threonine (119.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (1.02 g, 5.0 mmol) were dissolved in ether (2 mL) and stirred at 60 °C for 48 hours. Borane tetrahydrofuran complex (1 M, 5 mL, 5 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of water was added to quench the reaction and threonine amine-borane (compound 4) was isolated. The NMR spectrum is shown in the figure below. Figures 10-12 shown.
[0080] 1 H NMR (400MHz, D2O) δ3.80 (dq, J = 8.1, 6.4Hz, 1H), 2.92 (d, J = 7.9Hz, 1H), 1.77–1.34 (m, 3H), 1.20 (d, J = 6.5Hz, 3H). 13 C NMR (101MHz, D2O) δ172.8, 65.9, 60.4, 19.4. 11 B NMR (128 MHz, D2O) δ -21.2.
[0081] Example 5: Preparation of Isoleucine Amine-Borane
[0082]
[0083] Isoleucine (131.2 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (408.8 mg, 2.0 mmol) were dissolved in acetonitrile (3 mL) and stirred at 25 °C for 24 hours. Borane dimethyl sulfide complex (1 M, 1.5 mL, 1.5 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of ethanol was added to quench the reaction and isoleucine amine-borane (compound 5) was isolated. The NMR spectrum is shown in the figure below. Figures 13-15 shown.
[0084] 1 H NMR(400MHz,D2O)δ3.01–2.90(m,1H),1.67(ddd,J=11.9,9.4,5.0Hz,1H),1.57–1.02(m,5H),0.90–0.74(m,6H). 13 C NMR (101MHz, D2O) δ174.1,59.5,35.8,24.4,14.6,11.0. 11 B NMR (128 MHz, D2O) δ -21.9.
[0085] Example 6: Preparation of Leucine Amine-Borane
[0086]
[0087] Leucine (131.2 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (408.8 mg, 2.0 mmol) were dissolved in dichloromethane (3 mL) and stirred at 0°C for 48 hours. Borane tetrahydrofuran complex (1 M, 1 mL, 1.0 mmol) was added to the reaction mixture and stirred for another 48 hours. After the reaction was completed, 2 mL of methanol was added to quench the reaction and leucine amine-borane (Compound 6) was isolated.
[0088] 1 H NMR (400MHz, D2O) δ3.08 (t, J = 7.1 Hz, 1H), 1.68–1.48 (m, 2H), 1.47 (t, J = 7.0 Hz, 4H), 0.83 (dd, J = 6.5, 5.4 Hz, 6H). 13 C NMR (101MHz, D2O) δ178.7,61.7,41.6,24.4,21.8,21.7. 11 B NMR (128 MHz, D2O) δ -20.4.
[0089] Example 7: Preparation of valine amine-borane
[0090]
[0091] Valine (117.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (817.6 mg, 4.0 mmol) were dissolved in acetone (3 mL) and stirred at 45 °C for 36 hours. Borane dimethyl sulfide complex (1 M, 2 mL, 2.0 mmol) was added to the reaction mixture and stirred for 18 hours. After the reaction was completed, 2 mL of tert-butanol was added to quench the reaction and valine amine-borane (Compound 7) was isolated.
[0092] 1 H NMR (400MHz, D2O) δ2.96 (d, J = 5.3Hz, 1H), 2.07–1.93 (m, 2H), 1.79–1.09 (m, 1H), 0.94 (s, 4H), 0.93 (s, 3H). 13 C NMR (101MHz, D2O) δ176.1,59.5,31.1,19.2,17.8.
[0093] Example 8: Preparation of lysine amine-borane
[0094]
[0095] Lysine (146.2 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (204.4 mg, 1.0 mmol) were dissolved in tetrahydrofuran (3 mL) and stirred at 20°C for 24 hours. Borane tetrahydrofuran complex (1 M, 1 mL, 1.5 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of water was added to quench the reaction and lysine amine-borane (Compound 8) was isolated.
[0096] 1 H NMR (400MHz, D2O) δ3.67(t,J=6.1Hz,1H),2.65(t,J=7.5Hz,2H),1.83(dq,J=10.1,6.2Hz,2H),1.66–1.55(m,2H),1.47–0.88(m,5H). 13 C NMR (101MHz, D2O) δ175.4, 58.5, 40.1, 30.8, 27.2, 25.3.
[0097] Example 9: Preparation of Glutamic Acid Amide-Borane
[0098]
[0099] Glutamic acid (147.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (408.8 mg, 2.0 mmol) were dissolved in 1,4-dioxane (3 mL) and stirred at 30°C for 36 hours. Borane tetrahydrofuran complex (1 M, 1.5 mL, 1.5 mmol) was added to the reaction mixture and stirred for 48 hours. After the reaction was completed, 2 mL of ethanol was added to quench the reaction and glutamate amine-borane (Compound 9) was isolated.
[0100] 1 H NMR (400MHz, D2O) δ4.19–4.05(m,1H),2.31(ddd,J=8.9,7.3,4.4Hz,2H),2.15–2.02(m,2H),1.69–0.88(m,3H). 13 C NMR (101MHz, D2O) δ181.9, 175.9, 56.7, 34.0, 25.2.
[0101] Example 10: Preparation of tyrosine amine-borane
[0102]
[0103] Tyrosine (181.2 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (204.4 mg, 1.0 mmol) were dissolved in acetonitrile (3 mL) and stirred at 25 °C for 40 hours. Borane dimethyl sulfide complex (1 M, 3.5 mL, 3.5 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of isopropanol was added to quench the reaction and tyrosine amine-borane (Compound 10) was isolated.
[0104] 1 H NMR(400MHz,D2O)δ7.07(d,J=8.6Hz,2H),6.75(d,J=8.6Hz,2H),3.23(d,J=13.1Hz, 1H), 2.89 (dd, J=14.8, 4.8Hz, 1H), 2.81 (dd, J=14.2, 8.6Hz, 1H), 1.41–0.65 (m, 3H). 13 C NMR (101MHz, D2O) δ169.3,156.6,130.2,123.4,115.4,54.5,36.2.
[0105] Example 11: Preparation of serine amine-borane
[0106]
[0107] Serine (105.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (306.6 mg, 1.5 mmol) were dissolved in 1,4-dioxane (2 mL) and stirred at 20°C for 36 hours. Borane tetrahydrofuran complex (1 M, 1.5 mL, 1.5 mmol) was added to the reaction mixture and stirred for 24 hours. After the reaction was completed, 2 mL of water was added to quench the reaction and serine amine-borane (Compound 11) was isolated.
[0108] 1 H NMR (400MHz, D2O) δ3.95 (d, J = 3.7Hz, 1H), 3.81 (d, J = 5.0Hz, 1H), 3.20 (t, J = 4.4Hz, 1H), 1.73–0.86 (m, 3H). 13 C NMR (101MHz, D2O) δ172.8, 62.9, 58.4.
[0109] Example 12: Preparation of 4-dihydroxyboryl-L-phenylalanine (BPA) amine-borane
[0110]
[0111] 4-Dihydroxyboryl-L-phenylalanine (208.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (204.4 mg, 1.0 mmol) were dissolved in tetrahydrofuran (3 mL) and stirred at 25°C for 24 hours. Borane dimethyl sulfide complex (1 M, 3 mL, 3.0 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of methyl water was added to quench the reaction and 4-dihydroxyboryl-L-phenylalanine amine-borane (Compound 12) was isolated.
[0112] 1 H NMR (400MHz, D2O) δ7.50 (d, J = 7.4Hz, 2H), 7.13 (d, J = 7.5Hz, 2H), 3.48 (t, J = 6.2Hz, 1H), 2.71–2.51 (m, 2H), 1.26–0.97 (m, 3H). 13 C NMR (101MHz, D2O) δ172.1,138.3,136.2,133.4,130.5,57.6,36.3.
[0113] Example 13: Preparation of proline amine-borane
[0114]
[0115] Proline (115.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (306.6 mg, 1.5 mmol) were dissolved in 1,4-dioxane (3 mL) and stirred at 40°C for 24 hours. Borane tetrahydrofuran complex (1 M, 2 mL, 2.0 mmol) was added to the reaction mixture and stirred for 12 hours. After the reaction was completed, 2 mL of methanol was added to quench the reaction and proline amine-borane (Compound 13) was isolated.
[0116] 1 H NMR(400MHz,D2O)δ3.47-3.34(m,2H),2.86-2.77(m,1H),2.23-2.11(m,1H),1.95-1.82(m,2H),1.78-1.63(m,1H),1.16–0.94(m,3H). 13 C NMR (101MHz, D2O) δ173.4, 59.2, 46.7, 29.8, 24.6.
[0117] Example 14: Preparation of Alanine Amine-Borane
[0118]
[0119] Alanine (89.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (306.6 mg, 1.5 mmol) were dissolved in N,N-dimethylformamide (3 mL) and stirred at 10°C for 48 hours. Borane tetrahydrofuran complex (1 M, 2 mL, 2.0 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of ethanol was added to quench the reaction and alanine amine-borane (Compound 14) was isolated.
[0120] 1 H NMR (400MHz, D2O) δ3.09 (q, J = 7.1Hz, 1H), 1.37 (d, J = 7.2Hz, 3H), 1.18–0.93 (m, 3H). 13 C NMR (101MHz, D2O) δ176.4, 53.2, 17.6.
[0121] Example 15: Preparation of cysteine amine-borane
[0122]
[0123] Cysteine (105.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (204.4 mg, 1.0 mmol) were dissolved in 1,2-dichloroethane (3 mL) and stirred at 60°C for 24 hours. Borane tetrahydrofuran complex (1 M, 1 mL, 1.0 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of water was added to quench the reaction and cysteine amine-borane (Compound 15) was isolated.
[0124] 1 H NMR (400MHz, D2O) δ4.63 (dt, J = 6.8, 5.2Hz, 1H), 3.68–3.51 (m, 2H), 1.38–0.97 (m, 3H). 13 C NMR (101MHz, D2O) δ171.8, 56.9, 54.4.
[0125] Example 16: Preparation of aspartic acid amine-borane
[0126]
[0127] Aspartic acid (105.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (408.8 mg, 2.0 mmol) were dissolved in N-methylpyrrolidone (3 mL) and stirred at 25 °C for 36 hours. Borane dimethyl sulfide complex (1 M, 1 mL, 1.0 mmol) was added to the reaction mixture and stirred for 24 hours. After the reaction was completed, 2 mL of methanol was added to quench the reaction and aspartic acid amine-borane (Compound 16) was isolated.
[0128] 1 H NMR (400MHz, D2O) δ3.89 (dd, J = 3.75, 8.69Hz, 1H), 2.59-2.88 (m, 2H), 1.63–0.96 (m, 3H). 13 C NMR (101MHz, D2O) δ175.1, 173.4, 54.4, 35.4.
[0129] Example 17: Preparation of N-methylphenylalanine amine-borane
[0130]
[0131] N-methylphenylalanine (179.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (306.6 mg, 1.5 mmol) were dissolved in tetrahydrofuran (2 mL) and stirred at 30 °C for 36 hours. Borane tetrahydrofuran complex (1 M, 1 mL, 1.0 mmol) was added to the reaction mixture and stirred for 24 hours. After the reaction was completed, 2 mL of methanol was added to quench the reaction and N-methylphenylalanine amine-borane (Compound 17) was isolated.
[0132] 1 H NMR (400MHz, D2O) δ7.42–7.23(m,5H),3.38(t,J=6.5Hz,1H),3.05–2.99(m,2H),2.52(s,3H),1.52–1.17(m,3H). 13 C NMR (101MHz, D2O) δ172.2,138.0,129.3,128.1,125.6,65.0,37.3,33.5.
[0133] Example 18: Preparation of N,N-dimethylphenylalanine amine-borane
[0134]
[0135] N-methylphenylalanine (179.1 mg, 1.0 mmol) and N,O-bis(trimethylsilyl)acetamide (306.6 mg, 1.5 mmol) were dissolved in tetrahydrofuran (2 mL) and stirred at 30 °C for 36 hours. Borane tetrahydrofuran complex (1 M, 1 mL, 1.0 mmol) was added to the reaction mixture and stirred for 36 hours. After the reaction was completed, 2 mL of methanol was added to quench the reaction and N,N-dimethylphenylalanine amine-borane (Compound 18) was isolated.
[0136] 1 H NMR (400MHz, D2O) δ7.42–7.23(m,5H),3.38(t,J=6.5Hz,1H),3.05–2.99(m,2H),2.50(s,6H),1.72–1.25(m,3H). 13 C NMR (101MHz, D2O) δ173.1,137.6,129.0,127.9,126.0,64.6,37.3,35.9,33.5.
[0137] II. Verification of water solubility, safety and effectiveness of amino acid amine-borane compounds
[0138] 1. Water solubility test of amino acid amine-borane prepared in Examples 1 to 3
[0139] 200.0 μL of distilled water was added to 30.0 mg of compounds 1 to 3 and mixed to obtain suspensions; each suspension was ultrasonically treated for 2 h, then centrifuged at 5000 rpm for 10 min, 100 μL of the supernatant was taken and diluted to 5 mL, and the boron content in the supernatant was determined by inductively coupled plasma mass spectrometry (ICP-MS), and the average value was obtained after 6 times of repeating. At the same time, commercially available drug BPA was used as a control.
[0140] The test results showed that the water solubility of compound 1 was 52.36 g / L, the water solubility of compound 2 was 100.93 g / L, the water solubility of compound 3 was 88.25 g / L, and the water solubility of the commercially available boron drug BPA in the control group was 1.46 g / L.
[0141] The results showed that amino acid amine-borane compounds 1 to 3 had good water solubility, with the highest reaching 69.1 times that of commercially available BPA boron drugs.
[0142] 2. Cytotoxicity test of amino acid amine-borane prepared in Examples 1 to 8
[0143] This experiment uses mouse fibroblasts (L929 cells, purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences) for cytotoxicity tests. L929 cells were cultured in DMEM containing 10% (v / v) fetal bovine serum, 1% (v / v) penicillin and streptomycin. L929 cells were placed in a cell culture incubator at 37°C and 5% CO2. The cells were cultured and passaged for 3 to 5 generations before use. The viability of L929 cells was evaluated using an Alamar Blue kit. Generally, a cell survival rate of >75% indicates that the compound is not cytotoxic.
[0144] The compounds prepared in Examples 1 to 8 above were dissolved in sterile fetal bovine serum (FBS) buffer at a concentration of 10 mM, filtered and sterilized with a microporous membrane, and placed at 60°C for 24 hours for further sterilization, and then stored under sterile conditions. The prepared FBS solution of the compounds of Examples 1 to 8 at a concentration of 10 mM was diluted with DMEM culture fluid to obtain 0.5 mM, 1 mM, 2.5 mM and 5 mM DMEM culture fluids of the compounds of Examples 1 to 8. L929 cells were inoculated into a 96-well plate at a density of 1500 cells / well, and after culturing for 24 hours under the above culture conditions, the DMEM culture fluid was washed off, and the DMEM culture fluid containing different concentrations (0.5 mM, 1 mM, 2.5 mM and 5 mM) of the compounds prepared in Examples 1 to 8 above was added, and the cells cultured in the DMEM culture fluid without additional compound addition were used as blank controls, and the cells were co-cultured in an incubator for 24 hours. Subsequently, the cell viability was detected by using the Alamar Blue kit after 24 h of co-culture, and the fluorescence intensity of the culture solution at an emission wavelength of 600 nm under an excitation wavelength of 530 nm was measured by a microplate reader to evaluate the cell survival rate. The experimental results are as follows Figures 16 to 23 shown.
[0145] Depend on Fig.16 It can be seen that at lower culture concentrations (1 mM and 0.5 mM) of compound 1, the survival rate of L929 cells reached more than 80%, indicating that compound 1 has little cytotoxicity. Fig.17 It can be seen that at each culture concentration of compound 2, the survival rate of L929 cells reached more than 75%, indicating that compound 2 has no cytotoxicity at each concentration. Fig.18 It can be seen that at each culture concentration of compound 3, the survival rate of L929 cells reached more than 75%, indicating that compound 3 has no cytotoxicity at each concentration. Fig.19 It can be seen that at the culture concentrations of 2.5 mM, 1 mM and 0.5 mM of compound 4, the survival rate of L929 cells reached more than 80%, indicating that compound 4 has basically no cytotoxicity. Fig. 20 It can be seen that at the culture concentrations of 2.5mM, 1mM and 0.5mM of compound 5, the survival rate of L929 cells was not significantly different from that of the control group or was even higher than that of the control group, indicating that compound 5 has basically no cytotoxicity. Fig.21 It can be seen that at lower culture concentrations of compound 6 (1 mM and 0.5 mM), the survival rate of L929 cells was not significantly different from that of the control group, and was even higher than that of the control group, indicating that compound 6 had basically no cytotoxicity. Fig. 22 It can be seen that at a low culture concentration of compound 7 (0.5 mM), the survival rate of L929 cells was greater than 75%, indicating that compound 7 had little cytotoxicity. Fig.23It can be seen that at the culture concentrations of 2.5 mM, 1 mM and 0.5 mM of compound 8, the activity of L929 cells reached more than 80%, indicating that compound 8 has basically no cytotoxicity.
[0146] In summary, the various essential amino acid amine-boranes prepared by this method are substantially non-cytotoxic.
[0147] 3. Boron atom uptake experiment of amino acid amine-borane prepared in Examples 1 to 7 in 4T1 cells
[0148] In this experiment, tumor cell line mouse breast cancer cells (4T1 cells, purchased from Shanghai Cell Bank, Chinese Academy of Sciences) were used for boron atom uptake test. 4T1 cells were cultured in 1640 culture medium containing 10% (v / v) fetal bovine serum, and the cells were placed in a cell culture incubator at 37°C and 5% CO2. The cells were cultured and passaged for 3 to 5 generations before use.
[0149] The tumor cell line 4T1 in the logarithmic growth phase with a cell content of 80% to 85% was inoculated into a 6-well plate (1×10 6 cells). After the cells adhered to the wall, the cells were treated with 1,4-dihydroxyboronophenylalanine (BPA) at a concentration of 1 mM and the compounds prepared in Examples 1 to 7 above for 24 hours, and cells cultured in DMEM medium without adding compounds were used as blank controls. The culture medium was discarded and the cells were washed 3 times with PBS. After washing with PBS, 0.25% trypsin was added and digested at 37°C for 3 minutes. Conventional culture medium was added to stop the digestion, and the cell suspension was transferred to a centrifuge tube. It was repeatedly blown to form a single cell suspension. After counting, it was centrifuged at 1500 rpm for 5 minutes, and the supernatant was aspirated. Concentrated nitric acid (10 6 After the cells were digested for 2 hours, ultrapure water was added to dilute to 10 mL and filtered through a microporous filter. The zero point was adjusted with a sample that was not incubated with a boron-containing culture medium, and the boron concentration in the solution was determined by ICP-MS to calculate the intracellular boron concentration. Three samples were taken and the average value was calculated.
[0150] The experimental results are as follows Fig.24 As shown, in 4T1 cells, the intracellular boron concentration obtained by the control group BPA was 5.00 μg / 10 6 The intracellular boron concentration obtained by compound 2 (tryptophanamine-borane) was 133.85 μg / 10 6 The intracellular boron concentration obtained by compound 1 (phenylalanine amine-borane) was 91.65 μg / 10 6 cells, which is 18.3 times that of the control group BPA. The intracellular boron concentration obtained by compound 7 (valine amine-borane) was 35.67 μg / 10 6cells, which is 7.1 times that of the control group BPA. The intracellular boron concentration obtained by compound 6 (leucine amine-borane) was 22.33 μg / 10 6 The intracellular boron concentration obtained by compound 3 (methionine amine-borane) was 20.76 μg / 10 6 The intracellular boron concentration obtained by compound 4 (threonine amine-borane) was 13.00 μg / 10 6 cells, which is 2.6 times that of the control group BPA. The intracellular boron concentration obtained by compound 5 (isoleucine amine-borane) was 1.67 μg / 10 6 cells, and the BPA control group was 3.0 times that of that of the control group.
[0151] In summary, except for isoleucine and lysine, the experimental results of boron atom uptake of essential amino acid amine-borane in 4T1 cells were better than BPA, with the highest reaching 26.8 times that of BPA.
[0152] The above contents are only for explaining the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.
Claims
1. An amino acid amine-borane compound, characterized in that: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and stereoisomers, isotopic products and derivatives of the compound of formula (I) or a pharmaceutically acceptable salt thereof: Wherein, R is a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, an alkyl group containing a substituent, an aryl group containing a substituent or a heteroaryl group containing a substituent; R' is a hydrogen atom, an alkyl group or an alkyl group containing a substituent.
2. The amino acid amine-borane compound according to claim 1, characterized in that The pharmaceutically acceptable salt of the compound of formula (I) is its ammonium salt, lithium salt, sodium salt, potassium salt, rubidium salt, cesium salt, magnesium salt or calcium salt.
3. The amino acid amine-borane compound according to claim 1 or 2, characterized in that: The invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, and mixtures of enantiomers in any ratio.
4. The amino acid amine-borane compound according to any one of claims 1 to 3, characterized in that The isotopic products of the compounds of formula (I) or their pharmaceutically acceptable salts contain 10 B. 11 B. 12 C. 13 C. 18 O or 2 H atom.
5. The method for preparing the amino acid amine-borane compound according to any one of claims 1 to 4, characterized in that: The following steps are involved: 1) dissolving an amino acid and N,O-bis(trimethylsilyl)acetamide in an organic solvent to react to obtain a silicon-protected amino acid; 2) adding a borane complex to the reaction mixture of step 1) to obtain an amino acid amine-borane compound.
6. The method for preparing the amino acid amine-borane compound according to claim 5, characterized in that: The equivalent ratio of amino acid, N,O-bis(trimethylsilyl)acetamide and borane complex is 1:(1-5):(1-5).
7. Use of the amino acid amine-borane compound according to any one of claims 1 to 4 in the preparation of a drug or preparation for treating tumors, or in the preparation of a drug or preparation for inhibiting the progression of tumors.
8. Use of the amino acid amine-borane compound according to any one of claims 1 to 4 in the preparation of a pharmaceutical preparation for boron neutron capture tumor treatment.
9. The use according to claim 7 or 8, characterized in that: The tumor is glioblastoma multiforme, malignant meningioma, intramedullary spinal glioma, advanced or recurrent head and neck cancer, thyroid cancer, malignant melanoma, recurrent breast cancer, metastatic liver cancer, malignant brain tumor, osteosarcoma, lung cancer, squamous cell carcinoma of the skin or nasopharyngeal carcinoma.
10. The use according to claim 7 or 8, characterized in that: The pharmaceutical preparation is an injection prepared by mixing an amino acid amine-borane compound with physiological saline, phosphate buffer solution, sterile water or glucose solution.
Citation Information
Patent Citations
Synthesis methods of phosphorus-modified nucleic acids
CN102282155A
Methods and compositions for color stabilized distillate fuel oils
US5197996A
